491 documents

Read All
22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
Read More
23:15 , Mar 1, 2018 |  BC Extra  |  Politics & Policy

Biopharma wants another bite at the donut hole

Lobbyists for the biopharmaceutical industry are scrambling to use a must-pass spending bill as a vehicle to roll back provisions in a recently enacted law that would impose tens of billions of dollars in costs...
Read More
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
Read More
20:41 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages 3 and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...
Read More
23:20 , Sep 6, 2017 |  BC Extra  |  Company News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages three and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...
Read More
21:49 , Jul 27, 2017 |  BC Innovations  |  Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
Read More
21:16 , Jul 19, 2017 |  BC Extra  |  Company News

China adds drugs to reimbursement list

China's Ministry of Human Resources and Social Security (MoHRSS) has negotiated discounts for 36 high-cost, high-value drugs and added them to its national reimbursement drug list, according to Goldman Sachs analyst Richard Yeh. The drugs'...
Read More
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
Read More
20:11 , Apr 19, 2017 |  BC Extra  |  Politics & Policy

China releases list of drugs up for negotiation

China's Ministry of Human Resources and Social Security (MoHRSS) released its list of 44 high-cost, high-value drugs for which it will negotiate pricing with manufacturers before inclusion on its updated national reimbursement drug list (NRDL),...
Read More
03:07 , Feb 4, 2017 |  BioCentury  |  Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
Read More